Telix Pharmaceuticals Limited

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 05:18:29 13/03/2026 GMT			5-day change	1st Jan Change
11.29 ^AUD	+0.53%		+5.02%	+0.80%

03-10	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Investors Weigh Middle East War Signals, Oil Price Volatility	MT
03-10	Telix Says Part 1 of Late-Stage Trial of Prostate Cancer Treatment Achieves Primary Objectives	MT

Telix Pharmaceuticals Q4 Revenue Rises

Published on 01/20/2026 at 12:32 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Telix Pharmaceuticals Limited

03-10	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Investors Weigh Middle East War Signals, Oil Price Volatility	MT
03-10	Telix Says Part 1 of Late-Stage Trial of Prostate Cancer Treatment Achieves Primary Objectives	MT
03-10	Australian Shares Rebound; Telix Says First Part of Phase Three Study Confirms Safety Profile of Drug Candidate	MT
03-10	Telix Pharmaceuticals Expected to Present Data from First Part of Phase Three Study to Seek Investigational New Drug Amendment, Jefferies Says	MT
03-10	Telix Pharmaceuticals Limited Achieves Primary Objectives In Prostact Global Phase 3 Study Part 1	CI
03-10	Telix Pharmaceuticals Limited - Special Call
03-10	Telix Pharmaceuticals Says First Part Of Phase Three Study Confirms Safety Profile, Biodistribution, Dosimetry Of Drug Candidate, Shares Jump 7%	MT
03-10	Telix Pharmaceuticals says Prostact global phase 3 (part 1) achieves primary objectives	RE
03-09	ASX Preview: Australian Shares to Rise After Trump Remarks; Telix Pharmaceuticals Reports Positive Prostate Cancer Trial Results	MT
03-06	Boss Energy Drops to Sixth Most Shorted Stock on Australian Bourse from Second Position, ASIC Data Shows	MT
03-05	Telix Pharmaceuticals Limited - Special Call
03-02	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
02-27	Telix, University Hospital Essen Enter Partnership on AI Prognostics in Prostate Cancer	MT
02-27	Telix Pharmaceuticals Limited Joins Forces with University Hospital Essen on Promise-Pet: Optimizing Patient Management Through Ai-Enabled Psma-Pet Imaging	CI
02-27	Telix Pharmaceuticals Says Second Part of Prostate Cancer Study Enrolls Patients in Australia, Canada, New Zealand	MT

Chart Telix Pharmaceuticals Limited

Duration

Period

TLX: Dynamic Chart

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

Employees

1,152

Sector

Biotechnology & Medical Research

More about the company